Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and .
Tonix Pharmaceuticals Holding Corp.March 15, 2021 GMT
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled
Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in First Quarter 2021
Phase 1 Safety Study in Humans of TNX-1800 Expected to Start in Second Half 2021
At December 31, 2020, Cash and Cash Equivalents Totaled $77.1 Million;
Approximately $110 Million in Gross Proceeds Raised Subsequent to Year-End
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Leading Edge Materials Welcomes Governmental Review of Permitting Processes and Regulations
Leading Edge Materials Corp.March 15, 2021 GMT
Vancouver, March 15, 2021 – Leading Edge Materials Corp. (“Leading Edge” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) welcomes last week’s announcement from the Swedish Government1 on the launch of a governmental review of permitting processes and regulations to ensure a sustainable supply of critical raw materials from primary and secondary sources.
A press release from Ibrahim Baylan, Minister for Business, Industry and Innovation, announced the appointment of a special reviewer tasked with delivering a report based on their findings. The press release highlights the importance of critical raw materials for Swedish industry and especially those that are required to succeed with the climate transition. Wind po
Press release content from Accesswire. The AP news staff was not involved in its creation.
Roscan Gold Announces Overnight Marketed Public Offering
March 15, 2021 GMT
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
TORONTO, ON / ACCESSWIRE / March 15, 2021 / Roscan Gold Corporation (TSXV:ROS)(FSE:2OJ)(OTC Pink:RCGCF) (“Roscan” or the “Company”) is pleased to announce that it has launched an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Common Shares”). The Offering will be conducted through a syndicate of agents (the “Agents”) led by Clarus Securities Inc.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cape Fox Lodge and Baranof Fishing Partner to Bring Back Adventure!
Cape Fox CorporationMarch 15, 2021 GMT
Ketchikan, Alaska, March 15, 2021 (GLOBE NEWSWIRE) After spending over a year at home, are you looking to bring back vacation and adventure? Cape Fox Lodge and Baranof Fishing are partnering to bring the adventure back to your life in Alaska.
Now is the time to cast away your troubles and have that Alaskan adventure you have always wanted to take. Cape Fox Lodge is a luxurious retreat that has been providing food and lodging for traveling friends and guests for over 30 years. By partnering with Baranof fishing, we can give you lavish accommodations and fishing tour packages at reasonable prices.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business .
Shattuck Labs, Inc.March 15, 2021 GMT
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –
– Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –
AUSTIN, TX and DURHAM, NC, March 15, 2021 (GLOBE NEWSWIRE) Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided r